Core Insights - Daxor Corporation is expanding its ezBVA Lab service into three regional healthcare facilities across the U.S., enhancing blood volume analysis capabilities and improving patient outcomes while reducing costs [2][3] - The ezBVA Lab provides comprehensive blood volume analysis results within 24 hours for both inpatient and outpatient settings, showcasing the efficiency and effectiveness of Daxor's technology [2][3] - Daxor's BVA technology has been integrated into various healthcare settings, including a prominent Midwest academic medical center and a leading cardiovascular institute in New Jersey, indicating its growing significance in modern healthcare [3][6] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, with its BVA-100® being the only FDA-cleared diagnostic blood test for quantifying blood volume status [4] - Over 65,000 tests have been performed at leading hospital centers across the U.S., significantly reducing mortality and readmissions in heart failure and critical care [4] - Daxor is involved in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [4]

KORU Medical Systems (KRMD) Q4 2024 Earnings Call March 12, 2025 04:30 PM ET Company Participants Louisa Smith - PrincipalLinda Tharby - President and CEOTom Adams - Chief Financial OfficerMichaela Smith - Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareFrank Takkinen - Senior Research AnalystJason Bednar - Senior Research AnalystAnderson Schock - Research Analyst Operator Greetings, and welcome to the Coram Medical Systems Fourth Quarter and Ful ...

Core Insights - Daxor Corporation reported a strong financial performance for fiscal 2024, achieving a 116.5% increase in revenue compared to 2023, driven by robust demand for its diagnostic systems [4] - The company has successfully transitioned to cash-flow positive operations in Q1 of 2025, excluding non-cash expenses [4] - Daxor is focused on launching its next-generation blood volume analyzer, which is expected to enhance clinical workflows and open new market opportunities [2] Financial Highlights - The net asset value (NAV) per share increased to $7.25 for fiscal 2024 from $7.08 in 2023 [1] - Daxor signed 12 new accounts in 2024, resulting in a 60.1% growth in the number of diagnostic kits sold year-over-year [4] - The company secured a $2.5 million two-year contract from the Department of Defense, contributing to its commercial momentum [4] Operational Developments - Daxor's next-generation blood volume analyzer is set to be filed for FDA approval via the rapid 510(k) pathway, which will facilitate point-of-care blood volume measurements [2] - The first two months of 2025 saw record-breaking monthly kit revenue, indicating accelerating adoption of Daxor's products [4] - The company received over $350,000 in grants from NIH and Launch Tennessee to support ongoing research and development [4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, with its BVA-100 being the only FDA-cleared diagnostic blood test for quantifying blood volume status [3] - The company has performed over 65,000 tests at leading hospital centers across the U.S., significantly improving patient outcomes in various medical conditions [3] - Daxor is engaged in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care with the U.S. Department of Defense [3]